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Forum Review
Reproductive Hormones Modulate Oxidative Stress in
Alzheimer’s Disease
ANNA M. BARRON,1,2,3 STEPHANIE J. FULLER,2,3
GIUSEPPE VERDILE,1,2 3 and RALPH N. MARTINS1,2,3

ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by gradual cognitive decline, impairments in speech and language, and dysfunction in the sensorimotor systems, culminating in complete reliance
on nursing care. Oxidative stress, caused by an imbalance in the pro-oxidant/antioxidant mechanisms in the
body, has been implicated in AD pathogenesis, as in many other age-associated diseases such as atherosclerosis, Parkinson disease, and amyotrophic lateral sclerosis. Although the hormones estrogen, progesterone, testosterone, and luteinizing hormone are best known for their roles in reproduction, many studies show these
hormones have other roles, including neuroprotection. Changes in the levels of these hormones that occur in
reproductive senescence are hypothesized to increase risk of AD, as a result of reduced protection against oxidative insults. The A peptide, overproduction of which is thought to be a key pathogenic event in the development of AD, is neurotoxic, most likely due to its ability to promote oxidative stress. The reproductive hormones are known to influence A metabolism, and this review discusses the beneficial and detrimental effects
these hormones have on A production and oxidative stress, and their relevance in potential AD therapies. Antioxid. Redox Signal. 8, 2047–2059.

INTRODUCTION

A

LZHEIMER’S DISEASE (AD) is the most common form of
age-related dementia (59). It is a complex disorder,
with many molecular triggers synergistically culminating in a
final common pathway. Examination of the atrophied AD
brain reveals a vast range of pathological changes including
widespread neuronal loss, particularly in the hippocampus
and frontal lobes (59). Histopathologically, the AD brain is
characterized by extracellular senile plaques, intracellular
neurofibrillary tangles, and congophilic amyloid angiopathy
(59). Senile plaques are comprised mostly of aggregated deposits of a 39–42 amino acid peptide termed beta amyloid
(A), and are often surrounded by activated microglia and
degenerating neurons (reviewed in Ref. 126). A is also

found in deposits within and around blood vessels, and these
deposits comprise the congophilic amyloid angiopathy (59).
Neurofibrillary tangles are abnormal intracellular deposits of
hyperphosphorylated and polymerized forms of the cytoskeletal protein tau. The AD brain is under oxidative stress
and A is thought to play a major role in promoting oxidative
damage (24, 76, 79). This review will describe the role of reproductive hormones in the modulation of A levels and oxidative stress in AD.

OXIDATIVE STRESS IN AD
Oxidative stress is recognized as a major neuropathological feature of AD, and recent evidence indicates that it may
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indeed be one of the earliest pathological events in the disease process (89). For example, elevated levels of oxidative
stress markers have been reported in subjects with mild cognitive impairment, who exhibit a high conversion rate to AD
(61, 98). Oxidative stress has also been linked to several other
age-associated conditions such as atherosclerosis, certain
cancers, Parkinson’s disease, and familial amyotrophic lateral
sclerosis. The first report that oxidative stress plays a role in
AD was the discovery of elevated glucose-6-phosphate dehydrogenase activity in AD brains (76); this enzyme is known to
help defend against oxidative stress. Since this initial discovery, evidence of elevated levels of lipid peroxidation, as well
as protein and DNA oxidation, have been reported in AD
brains by several laboratories (reviewed in Ref. 97). Studies
of transgenic animal models of AD support the concept that
oxidative stress in AD, as increased levels of oxidative stress
markers have been found in these animals, coinciding with
amyloid deposits (113). The challenge now lies in characterizing the molecular mechanism(s) that drive these oxidative
changes in AD and finding therapeutic strategies to prevent
and overcome these changes.

REPRODUCTIVE HORMONES
MODULATE OXIDATIVE STRESS
Inherent gender differences in responses to oxidative
stressors suggest that reproductive hormones have the potential to modulate the pro-oxidant/antioxidant balance, and
thereby modulate the susceptibility to oxidative stress.
Women have been found to have lower lipid peroxide levels
than men of the same age (77) and animal studies have indicated that the female brain is more resistant to oxidative insults mediated by ischemic injury (48). These gender differences in oxidative stress susceptibility have been attributed to
reproductive hormones. Comparisons between pre- and postmenopausal women have detected age-independent increases
in levels of lipid peroxidation markers coupled with decreases in levels of antioxidants such as glutathione peroxidase, ascorbic acid, and -tocopherol (77, 110, 129). Similarly, elevated lipid peroxide levels have been reported in
women who have undergone surgically induced menopause
via ovariectomy, corroborating the hypothesized role of the
reproductive hormones in oxidative stress (132).

GENDER DIFFERENCES IN AD
Gender differences have also been reported in the incidence, clinical presentation, and pathology of AD. Whilst
gender differences in AD prevalence are difficult to interpret
due to gender differences in life expectancy, incidence studies
indicate that women are at greater risk of AD, particularly in
the older population (5, 100), and slightly more severe cognitive deficits have been reported in women compared to men
(54). Gender differences in levels of antioxidants and oxidative stress indicators have also been reported in AD. Levels of
the antioxidant enzymes superoxide dismutase and glutathione peroxidase are elevated in AD brains when compared

to controls, and additionally, when compared to their male
counterparts, female AD subjects have significantly greater
levels of these enzymes than male AD subjects (105). The elevated antioxidant levels observed in the female AD brains
were hypothesized to reflect a compensatory mechanism offsetting elevated pro-oxidant species (105). These gender differences in AD presentation and pathology may therefore reflect gender differences in vulnerability to oxidative insult,
perhaps mediated by gender differences in the levels of the
reproductive hormones following menopause compared to
andropause (male reproductive senescence).

HORMONE REGULATION AND
REPRODUCTIVE SENESCENCE
Steroidal sex hormones are predominantly synthesized in
the gonads under the regulatory control of the gonadotropin
hormones. Relatively small quantities of steroidal sex hormones are also produced in the adrenal glands, placenta,
heart, bone, adipose tissue, and brain (reviewed in Ref. 94).
The gonadotropins, luteinizing hormone (LH) and follicle
stimulating hormone (FSH), are synthesized in and secreted
from the pituitary, and act on the ovary and testes to stimulate
gonadal sex hormone production (Fig. 1). Following reproductive senescence (menopause), the gonads fail to synthesize and secrete steroidal sex hormones. Compensatory increases in nongonadal synthesis of steroidal sex hormones
have been recorded (85), nevertheless estrogen, progesterone,
and testosterone deficiencies occur following reproductive
senescence (26). Gonadotropin production and secretion also
increase markedly following reproductive senescence, in a
compensatory measure to stimulate sex hormone production;
however, this is inevitably unsuccessful (26, 78, 88, 122).

REPRODUCTIVE HORMONES AND AD
A large body of evidence indicates that estrogen, progesterone, and testosterone are neuroprotective, mediated at least
in part by antiamyloidogenic, antioxidative, and anti-inflammatory mechanisms. Consistent with the neuroprotective effect of the steroidal sex hormones, an association between
AD and depleted levels of estrogen in women, and testosterone in men, has been reported (55, 75, 91). Consequently, it
has been hypothesized that depleted sex hormone levels confer neurodegenerative susceptibility to AD. It has also been
speculated that the increased prevalence of AD in women is
the result of depleted estrogen levels following reproductive
senescence (reviewed in Ref. 73). Although superficially this
may seem paradoxical since men also experience testosterone
depletion following reproductive senescence, the loss of gonadal function and resulting sex hormone depletion generally
occurs abruptly in women, whereas men experience a gradual
depletion of testosterone over several decades (43, 78, 88,
122). Testosterone depletion in males is also highly variable
between individuals. Sex hormone depletion may also play an
important role in the development of other neurodegenerative
diseases that display similar gender predilections including
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FIG. 1. Reproductive hormone homeostasis: the hypothalamic pituitary axis. Gonadotropin releasing hormone
(GnRH) secreted from the hypothalamus binds with GnRH receptors on the pituitary activating production and secretion of
LH and FSH. LH and FSH interact with their respective receptors (LHR and FSHR) on the gonads to stimulate gonadal sex
hormone production (estrogen and progesterone from the
ovaries, testosterone from the testes). The gonadal sex hormones exert negative feedback on the hypothalamus and pituitary to inhibit further GnRH and gonadotropin secretion. LH
and FSH also exert negative feedback on the pituitary to inhibit
further gonadotropin production. Following reproductive
senescence, the gonads fail to produce significant quantities of
the gonadal sex hormones, abolishing the negative feedback
mechanisms keeping gonadotropin secretion in check.

amyotrophic lateral sclerosis, Parkinson disease, multiple
sclerosis, and AIDS-induced dementia (29).
Hormone replacement therapy (HRT) has been examined
as a potential preventative and therapeutic strategy in the
treatment of AD. Initial clinical trials of testosterone replacement therapy in older men have reported selective improvements in cognitive function (8, 57, 111), whilst testosterone
treatment was found to improve the ability to perform daily
tasks and reduce frailty in men with multi-infarct dementia
(8). Another study has also reported that testosterone improves cognitive function in a small cohort of subjects with
AD (117). Surprisingly, clinical trials have found HRT to be
of no benefit to female AD patients (87, 130). Even the potential preventative benefits of HRT are contentious. Whilst
many small studies have reported improved cognition and reduced prevalence of AD amongst HRT users (9, 60, 118), the
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recent Women’s Health Initiative clinical trial reported HRT
to be detrimental to cognitive function and increase AD risk
(32, 109). It has been argued that the long postmenopausal
delay prior to HRT initiation in the Women’s Health Initiative
study, with all participants 65 years and older, may explain
the detrimental effects observed (73). In light of this, another
HRT clinical trial (Kronos Early Estrogen Prevention Study)
has been initiated in perimenopausal women to re-address the
potential cardioprotective effects of HRT when administered
without a long postmenopausal delay (maximum 36 months
following final menses) (50). Other factors have also been
identified for consideration in interpretation of the WHI
study including the source of hormone (equine estrogens as
compared to synthetic human forms of these hormones) and
mode of delivery (cyclic vs. continuous) (73).
The neuroprotective properties of progesterone have been
most widely studied for the treatment of spinal chord and
traumatic brain injury. Although animal studies indicate that
natural progesterone is neuroprotective, the synthetic progesterone, medroxyprogesterone acetate (MPA), is not neuroprotective and has been shown to antagonize the neuroprotective
effects of estrogen (112). This is particularly interesting since
MPA was used in the WHI clinical trials; therefore, it is clear
there are a number of issues to be addressed before a definitive conclusion regarding the preventative benefit of HRT
against AD can be determined.
More recently, elevated postmenopausal and andropausal
LH have also been identified as potential neurodegenerative
factors in AD. Supporting this notion, significantly elevated
serum LH levels have been reported in dementia and AD subjects (19, 108). Elevated LH levels have also been confirmed
immunohistochemically in the hippocampus of AD brains
when compared to control brains, and the hippocampus is a
brain region particularly vulnerable to degeneration in AD
(18). Accordingly, it has been hypothesized that elevated LH
confers susceptibility to neurodegeneration in AD (19).
Sex hormone regulation and LH homeostasis are inextricably linked. These hormones also play a role in the modulation
of A peptide production (overproduction of which is
thought to be a key event in AD pathogenesis) and inflammatory processes, both of which may result in the generation of
oxidative stress.

AMYLOID PRECURSOR PROTEIN (APP)
AND A METABOLISM IN AD
Causative genetic mutations have been identified that account for <5% of AD cases (127). These include mutations in
the parent molecule of A, the amyloid precursor protein
(APP), and mutations in genes coding for the presenilin proteins that are involved in the proteolytic processing of APP
(67). These mutations lead to the increased production of A,
particularly the longer, more amyloidogenic form A1–42
(67). In AD, A peptides aggregate into insoluble fibrils, and
over time these deposit in the brain to produce the characteristic amyloid plaques. These studies, as well as many in vitro
and transgenic mice studies, have led to the “amyloid hypothesis,” which states that A accumulation is central to AD
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pathogenesis (67). Although plaques and neurofibrillary tangles are the recognized neuropathological hallmarks of the
disease, evidence suggests that in the early stages of the disease, the “toxic principle” of AD may consist of A dimers or
small soluble oligomers of the peptide, that have been shown
in many in vitro studies to have neurotoxic and oxidative
stress-inducing properties (82).

APP PROCESSING
AND OXIDATIVE STRESS
Many studies support the theory that the A peptide itself
is responsible, at least in part, for the AD-related oxidative
stress. It has been shown to be neurotoxic in many in vitro
models, most likely via the peptide’s ability to induce oxidative damage (51). A can induce the overproduction of superoxide radicals by interaction with vascular endothelial cells
(121). The peptide can also induce the intracellular accumulation of hydrogen peroxide in cultured neuroblastoma and
hippocampal neurons, and conversely antioxidants can atten-

uate A-mediated neurotoxicity (17, 41, 42). In studies of
synaptosomes and cultured cortical cells, A has also been
found to induce oxidative damage including lipid peroxidation (17). A also impairs mitochondrial function, potentially
increasing levels of free radicals generated via respiratory oxidative phosphorylation (1). Of relevance in the later stages
of AD, studies have found that amyloid plaques are a focus of
cellular and molecular oxidation (reviewed in Ref. 79).
The A peptide is a product of the proteolytic processing of
its much larger parent molecule APP (126). This transmembrane
APP molecule undergoes proteolytic processing by two competing pathways, the nonamyloidogenic and amyloidogenic pathways (Fig. 2). Sequential cleavage of APP by -secretase and secretase, respectively, thought to occur at the cell surface,
results in the secretion of soluble APP (-APPs) and nonamyloidogenic fragments. Alternatively, the cleavage of APP by
beta-site APP cleaving enzyme (BACE) and -secretase, thought
to occur following endocytosis of cell-surface APP, results in the
production of a different set of cleavage products including the
amyloidogenic A peptide (Fig. 2) (reviewed in Ref. 126).
It has been hypothesized that A accumulation increases
free radical generation beyond neural antioxidant capabili-

N

Non-Amyloidogenic
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Amyloidogenic
Pathway

APP
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C
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BACE
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AICD

FIG. 2. APP proteolytic processing pathways. Two competing pathways, the nonamyloidogenic and amyloidogenic pathways,
proteolytically cleave the majority of APP within the cell. In the nonamyloidogenic pathway, APP is cleaved with in the A domain
by -secretase to liberate a secreted form of APP (-APPs). A C-terminal fragment (C83/CTF) is left embedded in the membrane
for further cleavage into nonamyloidogenic fragments. In the amyloidogenic pathway, APP is first cleaved by BACE to liberate APPs. The C-terminal fragment (C99/-CTF) left embedded in the transmembrane (TM) is cleaved by the -secretase enzyme,
which consists of four proteins (PS1, Nicastrin, APH-1, and PEN-2) that interact with each other in a high molecular weight complex. This cleavage event liberates the A40/A42 peptides. It is thought that another fragment is also released termed the APP intracellular domain (AICD), that can translocate to the nucleus and activate gene transcription. Both pathways can be regulated by
reproductive hormones. Evidence suggests that high levels of estradiol (E2) or testosterone (T) drive APP processing towards the
nonamyloidogenic pathway and formation of the neuroprotective and neurotrophic -APPs metabolite. In contrast, high levels of
luteinizing hormone (LH) are thought to drive APP processing towards the amyloidogenic pathway and A formation.
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ties, thus initiating oxidative stress-stimulated neurodegenerative cascades (24). The accumulation of A can also elicit
secondary neurodegenerative cascades such as inflammation,
thereby indirectly contributing more oxidative stress (96). Interestingly, oxidative stress may itself stimulate the formation
of the more toxic insoluble A aggregates, thereby exacerbating the neurotoxic activity of A and potentially leading to a
self perpetuating cycle of A accumulation and free radical
generation (65). Accordingly, it has been postulated that decreasing A production and/or improving its clearance may
lower oxidative stress and prevent the development of the
neurodegenerative cascades thought to lead to AD (128).
In contrast to studies of A, studies of secreted -APPs
have shown this protein to have antioxidant and neuroprotective properties, as it can attenuate free radical generation and
suppress A toxicity. In vitro studies have shown that the production of -APPs stabilizes cellular calcium homeostasis
and protects neurons from metabolic, excitotoxic, and oxidative insults (41, 80). This protective effect of -APPs extends
to in vivo studies, which have reported that the nonamyloidogenic APP metabolite reduces damage to hippocampal neurons following forebrain ischemia in rats (114).

REPRODUCTIVE HORMONES
AND APP METABOLISM
The reproductive hormones, estrogen, testosterone, and
LH, all influence the metabolism of both the neurotoxic A
peptide and the neuroprotective APP fragment, -APPs. Estrogen has been reported to increase the secretion of -APPs
(56, 131), and to cause a decrease in A production in cultured human neuroblastoma and cerebrocortical neurons (56).
In addition to promoting the nonamyloidogenic APP processing pathway, estrogen has also been shown to inhibit APP
overexpression following ischemic injury (106), in turn reducing substrate for APP processing and subsequent A production. Apart from its effects on A production and accumulation, estrogen also directly inhibits the neurotoxicity of the
peptide (16, 40, 47). In vivo, estrogen depletion (induced via
ovariectomy) results in significantly elevated A levels, particularly the more toxic A1–42 species, an effect that is partially reversed following estrogen replacement (68, 95, 137).
Estrogen may also influence A accumulation via nonestrogenic receptor-mediated mechanisms since the biologically
inactive 17-estradiol can similarly reduce A levels (68). It
is conceivable that estrogen reduces A accumulation in the
intact animal through modulation of both A production and
clearance. In support of this, estrogen has been found to stimulate A clearance and degradation by microglial phagocytosis (52, 69). Correspondingly, increased A burden and impaired microglial A clearance has been reported in an
estrogen-deficient transgenic mouse model of AD (133). In
this study, estrogen deficiency was induced by crossbreeding
transgenic mice overexpressing APP with aromatase knockout mice, aromatase being an enzyme responsible for converting testosterone to estrogen. However, in direct contradiction, another recent study has reported that estrogen depletion
induced by ovariectomy had no significant effect on A bur-
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den in a transgenic mouse model of AD (45). This discrepancy may result from differences in neural estrogen status,
since Yue et al. (133) found that ovariectomy was insufficient
to deplete estrogen levels in brain homogenate, whereas the
aromatase knockout mice exhibited significantly depleted
central and peripheral estrogen levels. It is interesting to note
that although ovariectomy is the commonly used experimental model of estrogen deficiency, it appears that at least in
some circumstances ovariectomy does not induce estrogen
depletion in the central nervous system. High estrogen activity has been demonstrated in the brain of ovariectomized
mice relative to other body regions using the estrogenresponsive element-luciferase mouse model, which has been
engineered to express the nonmammalian luciferase protein
in response to classical estrogen receptor activation (27). This
confirms that central and peripheral estrogen homeostasis is
not necessarily synergistic, this is not a new concept, and this
observation was the first evidence for de novo synthesis of estrogen and other hormones in the brain (reviewed in Ref. 84).
Hence, peripheral estrogen status may not be an accurate indication of central nervous system estrogen status. Depleted
estrogen levels have in fact been reported in brain homogenate of female AD patients (133).
Testosterone has also been implicated in the metabolism of
APP and A production (39, 44). In a manner similar to estrogen, testosterone treatment increases secretion of soluble
-APPs and simultaneously decreases A production (39). In
this study, the duration (but not the dose) of testosterone
treatment was found to correlate negatively with A production (39). Since testosterone can be converted to estrogen by
aromatase in the brain, it is possible that estrogen synthesized
from the testosterone may be responsible for such effects on
APP metabolism. Aromatase inhibitors and dihydrotestosterone are being used to investigate whether testosterone has
a direct role in the modulation of A metabolism. Estrogen
and testosterone depletion induced via chemical castration in
men undergoing prostate cancer treatment is accompanied by
a significant increase in plasma A levels (4), and in men
with impaired memory function, free testosterone levels have
been found to correlate negatively with plasma A levels
(38). Interestingly, no correlation was found between A levels and estradiol levels in this study, implying that testosterone is not influencing A metabolism entirely via its conversion to estrogen. Nevertheless, human studies such as these
substantiate the purported roles of both estrogen and testosterone in the regulation of A burden.
Unlike estrogen and testosterone, LH has been implicated
in the promotion of amyloidogenic processing of APP (20).
LH treatment of cultured human neuroblastoma cells results
in dose-dependent increases in the accumulation of A and
amyloidogenic APP C-terminal fragments, whilst decreasing
secretion of soluble -APPs (20). Leuprolide treatment,
which inhibits both gonadotropin and estrogen production,
has been used to study the effect of LH suppression on A
production in female mice (20, 25). LH suppression was
found to decrease brain A levels, particularly the longer,
more toxic A1–42 species (20, 25). This result was surprising since estrogen depletion is known to be associated with
elevated A levels, yet despite estrogen depletion induced by
chemical gonadoectomy, A levels were reduced. Casadesus
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et al. (25) argued that this demonstrates LH has a much
greater capacity to modulate A levels than the sex hormones. If so, the gonadectomy model of reproductive senescence should be reconsidered since LH and sex hormone homeostasis are intrinsically linked. Ideally, new models need to
be developed to discern the individual contributions of LH
and each of the gonadal sex hormones in neurodegenerative
processes.
Since A has been identified as a key protein in AD pathogenesis, potentially even playing a role in the initiation of the
neurodegenerative process, considerable drug development
has focused upon modifying the production and metabolism
of this protein (92). Given the antiamyloidogenic properties
of estrogen and testosterone, HRT may help minimize A
burden and consequently reduce oxidative injury. However, in
light of the recent evidence indicating that LH potently facilitates A production, irrespective of gonadal sex hormone status, gonadotropin-suppressing agents such as leuprolide may
have greater antiamyloidogenic potential than the gonadal sex
hormones (reviewed in Ref. 14). Accordingly, leuprolide has
recently been shown to attenuate cognitive decline and A
deposition in AD transgenic mice and is currently undergoing
clinical trials for the treatment of AD (25).

ANTIOXIDANT PROPERTIES OF THE
GONADAL STEROID HORMONES
Estrogens have been coined ‘natural antioxidants’ since
they have been demonstrated to inhibit lipid peroxidation in a
variety of biological systems. In microsomal lipid preparations, estrogens have been reported to inhibit iron-induced
lipid peroxidation (116). Similar antioxidant properties of estrogens have been reported in tissues of the central nervous
system. In vitro, 17-estradiol is a more potent inhibitor of
oxidative stress than -tocopherol in a range of neuronal cell
models, protecting against oxidative damage and cell death
mediated by the reactive oxygen species, hydrogen peroxide
(15, 16). 17-Estradiol and estriol have also been demonstrated to increase neuronal survival and reduce lipid peroxidation in response to iron-induced oxidative stress (40), and
to decrease mitochondrial production of reactive oxygen
species in a dose-dependent manner (28). Furthermore, 17estradiol inhibits iron induced lipid peroxidation in both rat
and human brain homogenates (124).
Although some of the neuroprotective effects of estrogen
that have been documented are the result of classical estrogen-receptor mediated signaling pathways, the antioxidant
properties of estrogens are mediated by receptor-independent
mechanisms (15). The concentrations of estrogens necessary
to elicit these antioxidant effects in both the central nervous
system and peripheral biological systems far exceed normal
physiological concentrations, indicating that these neuroprotective properties are not mediated by the estrogen receptor
(15). Supporting this notion, the antioxidant effects of the estrogens have been confirmed in neuronal cell lines that do not
express estrogen receptors (16). Furthermore, the antioxidant
properties of estrogens cannot be significantly attenuated by
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co-administration of a competitive estrogen receptor antagonist, or a protein synthesis inhibitor (28, 102, 115). Biologically inactive estrogen forms (with respect to the estrogen receptor) such as 17-estradiol also exhibit antioxidant activity,
again indicating receptor-independent antioxidant activity
(15, 102). Comparisons of the antioxidant capacities of estrogens in neuronal cell culture have led to the identification of
the hydroxyl group located at position 3 of the phenoxyl ring
of estrogen as an important structural feature for estrogenic
antioxidant activity (15, 101). The phenolic structure of estrogens enables the direct scavenging of free radicals by the donation of hydrogen to lipid peroxyradicals, thus terminating
oxidative chain reactions (115, 116).
In direct contrast to the free radical scavenging capacity of
estrogens, some studies have implicated high concentrations
of estrogens in metabolic reactions that generate free radicals
(70). Estradiol can be enzymatically metabolized into catechol estrogens, which have an additional hydroxyl- or
methoxy- group substituted in the ortho- position of the phenolic hydroxyl group of the estrogen (70). The hydroxyl- (but
not methylated-) substituted catechol estrogens are readily
oxidized, and undergo redox cycling to produce free radicals
(70). Elevated levels of estrogens result in increased catechol
estrogen redox cycling, thus promoting the formation of the
reactive oxygen species (70). These processes have been of
interest in cancer research, due to the potential oxidative
damage resulting from elevated estrogen levels in tissues that
readily catalyze catechol estrogen formation (70, 71). The
physiological significance of these metabolic pathways in the
brain is not well understood; however, catechol estrogens
have been detected throughout the brain (93) and limited oxidative metabolism of catechol estrogens has been demonstrated in brain microsomes (58). Whilst the antioxidant
properties of supra-physiological estrogen levels are well
documented, we can only speculate about the potential prooxidant properties of estrogen in the brain. The potential
long-term effects of supra-physiological estrogen concentrations must be determined prior to considering the clinical use
of estrogens as an antioxidant.
The potential antioxidant effects of the other steroidal hormones, progesterone and testosterone, have also been explored. Progesterone was found to be far less effective at inhibiting lipid peroxidation and neural death than either
estradiol or estriol (40). However, slight antioxidant properties
of progesterone occur in response to iron-induced oxidative
stress in neural cells, whilst testosterone offers no neuroprotective benefit (40). Similarly, progesterone but not testosterone reduces iron-induced lipid peroxidation significantly in
cultured hippocampal cell homogenates; however, neither progesterone nor testosterone elicited any effect on iron-induced
lipid peroxidation in human brain homogenates (124). Progesterone does not improve neuronal survival following hydrogen
peroxide treatment (16), yet testosterone exhibits neuroprotective effects in cerebellar granule cells against oxidative insults
mediated by the reactive oxygen species, hydrogen peroxide
and nitric oxide (NO) (2, 3). These neuroprotective effects
were suggested to be mediated by estrogen, following the conversion of testosterone to estrogen by aromatase (7). However,
the antioxidant properties of testosterone can be attenuated by
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flutamide, an androgen receptor antagonist (2). Furthermore,
unlike testosterone, estrogen does not yield any neuroprotective effect in the cerebellar granule cell oxidative stress model
(3). Testosterone is now thought to mediate its antioxidant effects by upregulation of the antioxidant enzymes superoxide
dismutase and catalase through the androgen receptor, rather
than via conversion to estrogen or via direct scavenging activity (2, 3). This is supported by evidence that testosterone treatment results in significant elevations of the superoxide dismutase and catalase enzymes in the cerebellum (2, 3).
Testosterone has also been implicated in the regulation of glutathione, with increased levels reported in rat brain homogenate following testosterone treatment (6). Whilst the
neuroprotective effect of testosterone is well established, further assessment of the underlying mechanisms is necessary, to
determine the degree to which neuroprotection is afforded by
its antioxidant properties.
In addition to acting as a free radical scavenger, estrogen
has also been implicated in the regulation of endogenous antioxidants and enzymes associated with their metabolism
(103, 104). Estrogen dose-dependently increases glutathione
levels in glial, hippocampal, and cortical neuron cultures
(104). Catalase activity is differentially affected by estrogen
in glial and hippocampal cultures, estrogen treatment increases catalase activity in glial cells, yet decreases catalase
activity in hippocampal cells (103). In vivo, ovariectomy has
been associated with increased catalase levels yet unchanged
glutathione and superoxide dismutase levels (86, 90). Postmenopausal women also have altered levels of antioxidant enzymes compared to women of reproductive age (77, 129) and
glutathione peroxidase levels correlate positively with serum
estradiol levels in women on HRT (77). Premenopausal
women have also been reported to possess significantly
higher glutathione peroxidase levels than males of the same
age (77). As previously discussed, evidence indicates that
compensatory mechanisms have already resulted in significantly elevated glutathione levels in AD brains. It is not
known if HRT would increase glutathione levels even further
in AD patients, and if so, whether this would elicit any clinical benefit in the treatment of AD.
Clinical research has linked antioxidant therapy to the
prevention and delay of AD (reviewed in Ref. 23). The clinical use of estrogens as antioxidants may be limited due to
their hormonal actions, including their oncogenic effects on
reproductive tissues, and their feminizing effects in men.
Furthermore, the high doses of estrogen necessary to elicit
antioxidant activity have the potential to increase free radical production through catechol estrogen metabolism when
administered long-term. Synthetic estrogens with greater
scavenging activity have already been developed for use in
cancer treatments, to eliminate potential problems arising
from increased estrogenic action through classical signaling
pathways (46). Selective estrogen receptor modulators
(SERMS) have been developed for the treatment of hormonal driven cancer to antagonize estrogenic effects on reproductive organs, whilst preserving the beneficial actions
of estrogen on other organs (120). These compounds may
prove clinically useful in antioxidant therapy for the prevention and delay of AD.
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NEUROINFLAMMATION AND
REPRODUCTIVE HORMONES
Chronic inflammation has been identified as an important
neurodegenerative process contributing to AD. For example,
inflammatory molecules including cytokines are upregulated
in AD brains, and activated astrocytes and microglia are observed within and in close proximity to senile plaques (81).
Inflammatory molecules secreted by activated astrocytes and
microglia are potentially toxic and provide yet another source
of oxidative stress. Microglial activation provokes respiratory
burst activity, resulting in the production of the superoxide
anion, which can then subsequently be converted to other reactive oxygen species such as hydrogen peroxide, or the very
potent hydroxyl radical (10). Activated microglia also secrete
the reactive nitrogen species, NO, which is synthesized by inducible nitric oxide synthase (iNOS). Similarly, astrocytes
have been implicated in the production of NO, in addition to
playing a pivotal role in mediating microglial activation (10).
Activation of inflammatory processes in AD may be the result
of A deposition (96), a notion supported by evidence that
microglia may play a role in the phagocytosis and degradation of this peptide (35). Conversely, there is also evidence
that A deposition is the result of inflammation since activated microglia upregulate APP expression resulting in increased production of A (11). Whilst these inflammatory
processes may lead to oxidative stress, oxidative stress also
triggers inflammatory responses including astrocytic and microglial activation, potentially amplifying neurodegenerative
cascades.
It is interesting to note that inflammation can influence reproductive hormone homeostasis, and likewise, the reproductive hormones can influence the regulation of inflammatory
reactions (34). For example, altered immune responses have
been noted during menopause, and it has been found that
HRT can reverse these changes (64). Furthermore, immune
suppression during pregnancy is believed to be mediated by
the reproductive hormones (72). The monthly cyclic hormone
changes in women are also associated with changes in inflammatory markers, including elevated free radical production immediately prior to ovulation (107). The role of estrogen in vascular inflammation has received a lot of attention
because of the potential implications for the modulation of
cardiovascular disease risk. Similarly, the reproductive hormones have been implicated in the modulation of inflammatory responses in the central nervous system. Evidence indicates that the sex hormones and LH have opposite effects on
inflammatory processes—a relationship between these hormones that is now being reported regularly. Estrogen and testosterone have an anti-inflammatory activity, inhibiting the
activation of microglia and astrocytes, whilst LH is implicated in pro-inflammatory signaling pathways.
Neurosteroids and gonadal sex hormones modulate inflammatory responses of astroglia following neural injury.
The gonadal hormones, 17-estradiol, progesterone, and
testosterone, have all been shown to decrease reactive gliosis in ovariectomized or castrated rats following penetrating
brain injury (36). Similarly, 17-estradiol, progesterone,
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dehydroepiandrosterone (DHEA), and pregnenolone have
all been found to decrease reactive gliosis in castrated male
rats in response to penetrating brain injury, indicating the
hormone treatment inhibited astrocyte proliferation and/or
migration (36). In this study the neuroactive steroid, DHEA,
was found to be the most potent inhibitor of reactive gliosis
(36). There is also evidence that brain injury upregulates de
novo synthesis of estrogen from testosterone in astrocytes
(37), indicating that in this model at least some of the effects of testosterone may be due to its conversion to estrogen. Neurosteroids and gonadal sex hormones also have the
capacity to induce morphological changes in astrocytes
(30). 17-Estradiol, testosterone, and pregnenolone, but not
progesterone, have been found to increase the number of
GFAP-immunoreactive astrocyte processes, perhaps indicative of astrocyte arborization (30). It is clear that estrogen
not only has the capacity to suppress reactive gliosis following injury, but can also modulate potential neuroprotective
activities of astrocytes.
Estrogen has also been implicated in the regulation of a
wide range of microglial functions, including expression of
cytokines, cell surface molecules, apoptotic signaling pathways, and free radical generation (31). Cultured microglial
cells exhibit respiratory burst activity, phagocytic activity,
iNOS expression, and subsequent NO production in response to inflammatory stimuli, all of which can be inhibited by estrogen in a dose-dependent manner (127, 129).
These studies suggest that in vivo production of reactive
oxygen and nitrogen species by activated microglia could be
inhibited by estrogen treatment, thereby reducing the oxidative burden caused by chronic inflammatory responses.
Similarly, estrogen has been implicated in the modulation of
NO production from peripheral macrophages (53). Preincubation of microglial cultures with DHEA also decreases
NO secretion, but not iNOS expression (12). The inhibitory
effects of estrogen on microglial activation are dependent
upon the estrogen receptor, since the biologically inactive
17-estradiol has no effect on microglial responses (21) and
estrogen receptor antagonists abolish the inhibitory effects
of estrogen (125). It has been hypothesized that the estrogen
receptor acts through the mitogen activated protein kinases
(MAPKs) to moderate microglial responses, since MAPK
inhibitors also attenuate the effects of estrogen on microglial activation (21). Interestingly, estrogen was found to
attenuate microglial activation only when estrogen treatment was given to the cultures prior to inflammatory insult,
indicating estrogen does not have the capacity to modulate
inflammatory reactions once microglial activation has been
initiated (125).
The LH receptor has been found to be expressed on a diverse range of immune cells throughout the body, suggesting
that the immune system is a target for the gonadotropin hormones. Immune cells that express LH receptors include blood
leukocytes (72, 135), follicular and endometrial macrophages
(136), and macrophages of the human brain (22). A disparate
range of effects of the gonadotropin hormones on immune responses in the periphery has been described. Much research
has focused upon the role of human chorionic gonadotropin
(hCG) in inflammatory responses due to its role in immunosuppression during pregnancy. The effects of hCG on periph-
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eral inflammatory processes may provide insight into potential effects of LH, as both hormones mediate their biological
actions through a common receptor, the LH receptor. HCG
has been reported to dose dependently and reversibly inhibit
lymphocyte proliferation in response to inflammatory stimuli
(49). Furthermore, in vitro investigations have found that
high concentrations of hCG stimulate the production of the
anti-inflammatory cytokines interleukin-8 and interleukin-2
from blood leukocytes (63). In contrast to hCG, however, LH
has been implicated in pro-inflammatory and pro-oxidant
generation, which is believed to play an important role in luteolysis and ovulation. For example, LH dose-dependently increases secretion of reactive oxygen and nitrogen species
from human blood leukocytes (107). Gonadotropin-mediated
increased production of reactive nitrogen species may be the
result of iNOS upregulation, since hCG has been demonstrated to upregulate iNOS expression in macrophages (62).
It is evident that in the periphery the gonadotropins have
pluripotent effects on inflammation, differentially potentiating or suppressing inflammation depending on conditions
and tissue type.
Whilst researchers have suggested LH has a potential role
in the regulation of inflammatory reactions in the brain (13),
there has been limited investigation. Although LH receptors
have been detected on brain macrophages, no studies have investigated the effect of LH on these cells. In immortalized
hippocampal cultures, binding to the LH receptors mediates
the upregulation of 5-lipoxygenase, an enzyme important in
pro-inflammatory signaling pathways (134). Lipoxygenases
are lipid peroxidizing enzymes that metabolize arachidonic
acid, generating free radicals and inflammatory leukotrienes.
Further investigation is required to confirm if LH receptordependent upregulation of 5-lipoxygenase induces the classical lipoxygenase signaling pathways, leading to the production of pro-inflammatory and pro-oxidant species. LH has
been found to activate similar signaling pathways in gonadal
tissue, where LH receptor-dependent cAMP/protein kinase A
phosphorylation subsequently activates the lipoxygenase/
arachidonic acid signaling pathway (83, 119). 5-Lipoxygenase is expressed at particularly high levels in the hippocampus and the cerebellum (66), and age-related dysregulation of
5-lipoxygenase transcription results in increased 5-lipoxygenase expression in aged animals (99, 123). Therefore, it
may be conceivable that elevated LH levels that occur following reproductive senescence may increase 5-lipoxygenase
signaling in the LH receptor-rich hippocampus, stimulating
inflammation and oxidative stress. In light of the age-related
increase in 5-lipoxygenase expression, lipoxygenase inhibitors
have been recognized as potentially useful in the treatment of
AD (74).
The risks associated with long-term HRT diminish the potential for the use of estrogen as an anti-inflammatory agent
in the treatment of AD. Since estrogen mediates its antiinflammatory activity via the estrogen receptor, the synthetic
estrogens–selective estrogen receptor modulators–will not
mimic the anti-inflammatory properties of estrogen. Furthermore, given that estrogen cannot alter microglial activation
once an inflammatory response has been initiated, the antiinflammatory benefits of estrogen may be limited to prevention rather than treatment.
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CONCLUSIONS
A diverse and complex network of inextricably linked
neurodegenerative processes contribute to the generation of
oxidative stress in AD. It is likely that multiple factors combine to create a neural environment that facilitates oxidative
injury; although in some instances a single initiating factor
may be sufficient to trigger the neurodegenerative cascade.
According to the popular AD hypothesis, the “amyloid hypothesis,” oxidative stress and inflammation are closely
linked but secondary to the primary cause, which is the accumulation of A. However, oxidative stress induced by other
factors can also contribute to inflammation and amyloidogenesis, initiating a vicious cycle.
Dysregulation of the reproductive hormones, estrogen, progesterone, testosterone, and LH, has been associated with AD
etiology and pathology. Regulation of these hormones is
tightly linked, and following reproductive senescence gonadal sex hormone depletion is coupled to elevated LH levels. Given the neuroprotective mechanisms of gonadal sex
hormones described here, including antioxidant, anti-inflammatory, and anti-amyloidogenic properties, it seems surprising that the recent Women’s Health Initiative clinical trial has
found HRT to be detrimental to cognitive health in women

2055
(32, 109). If the clinical neuroprotective benefit of HRT is to
be definitively clarified, dosage and duration of treatment
will need to be offset against risks of potential negative effects associated with long-term HRT, including increased risk
of breast cancer, pulmonary embolism, and stroke. Further,
since estrogen has been identified as a potential proconvulsive, the cost–benefit of estrogen use should be individually
assessed in patients with seizure disorders (reviewed in Ref.
33). Whilst the potential benefits of HRT may be revisited to
resolve issues associated with the age at initiation of HRT, the
amyloidogenic and potentially inflammatory properties of
LH may also in part help explain the inconsistencies in the effects of HRT on AD risk. It is conceivable that the combined
effects of the sex steroids and gonadotropins may influence
the susceptibility to and progression of neurodegeneration.
The research reviewed here indicates that elevated sex hormone levels combined with low cycling LH levels during the
reproductive years may promote antioxidant activity, suppress inflammation, and reduce A accumulation (Fig. 3).
Following reproductive senescence, the depleted sex hormones combined with elevated LH levels promote A production and inflammation, and potentially exacerbate oxidative stress (Fig. 4). Given the diverse actions of the
reproductive hormones, combinational hormone therapy may
prove to be more efficacious in the prevention of AD, though
this notion needs to be tested in further studies.
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with oxidative stress pathways
during reproductive senescence. Following reproductive
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that can subsequently lead to
both oxidative stress and inflammation. It is also possible that
LH may stimulate pro-inflammatory signaling pathways in the
brain, which also can lead to the
generation of free radicals and
thus oxidative stress.

Antioxidant

REFERENCES
1. Abramov AY, Canevari L, and Duchen MR. Beta amyloid peptides induce mitochondrial dysfunction and oxidative stress in
astrocytes and death of neurons through activation of NADPH
oxidase. J Neurosci 24: 565–575, 2004.
2. Ahlbom E, Prins GS, and Ceccatelli, S. Testosterone protects
cerebellar granule cells from oxidative stress-induced cell death
through a receptor mediated mechanism. Brain Res 892: 255–
262, 2001.
3. Ahlbom E, Grandison L, Bonfoco E, Zhivotovsky B, and Ceccatelli S. Androgen treatment of neonatal rats decreases susceptibility of cerebellar granule neurons to oxidative stress in vitro.
Eur J Neurosci 11: 1285–1291, 1999.
4. Almeida O, Waterreous A, Spry N, Flicker L, and Martins RN.
One year follow-up study of the association between chemical
castration,sex hormones, beta-amyloid, memory and depression
in men. Psychoneuroendocrinology 29: 1071–1081, 2004.
5. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A,
Copeland JRM, Dartigues J–F, Kragh–Sorensen P, Baldereschi M,
Brayne C, Lobo A, Martinez–Lage JM, Stijnen T, and Hofman A.
Gender differences in the incidence of AD and vascular dementia:
The EURODEM Studies. Neurology 53: 1992–1997, 1999.
6. Atroshi F, Paulin L, Paalanen T, and Westermarck T. Glutathione
level in mice brain after testosterone administration. Adv Exp
Med Biol 264: 199–202, 1990.
7. Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, and
Garcia–Segura LM. Brain aromatase is neuroprotective. J Neurobiol 47: 318–329, 2001.
8. Azuma T, Nagai Y, Saito T, Funauchi M, Matsubara T, and
Sakoda S. The effect of dehydroepiandrosterone sulfate administration to patients with multi-infarct dementia. J Neurol Sci 162:
69–73, 1999.

9. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, Scarlato G, and Amaducci L. Estrogen-replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on
Aging. Neurology 50: 996–1002, 1998.
10. Banati RB, Gehrmann J, Schubert P, and Kreutzberg GW. Cytotoxicity of microglia. Glia 7: 111–118, 1993.
11. Banati RB, Gehrmann J, Czech C, Mönning U, Jones LL, König
G, Beyreuther K, and Kreutzberg GW. Early and rapid de novo
synthesis of Alzheimer beta A4-amyloid precursor protein (APP)
in activated microglia. Glia 9: 199–210, 1993.
12. Barger SW, Chavis JA, and Drew PD. Dehydroepiandrosterone
inhibits microglial nitric oxide production in a stimulus-specific
manner. J Neurosci Res 62: 503–509, 2000.
13. Barron A, Verdile G, and Martins RN. The role of gonadotropins
in Alzheimer’s disease: potential neurodegenerative mechanisms. Endocrine 29: 257–269, 2006.
14. Barron A, Verdile G, and Martins RN. Gonadotropins: potential
targets for preventative and therapeutic interventions in Alzheimer’s disease. Fut Neurol 1: 189–202, 2006.
15. Behl C, Skutella T, Lezoualc’H F, Post A, Widmann M, Newton
CJ, and Holsboer F. Neuroprotection against oxidative stress by
estrogens: structure-activity relationship. Mol Pharmacol 51:
535–541, 1997.
16. Behl C, Widmann M, Trapp T, and Holsboer F. 17-beta Estradiol
protects neurons from oxidative stress-induced cell death in
vitro. Biochem Biophys Res Commun 216: 473–482, 1995.
17. Behl C, Davis JB, Lesley R, and Schubert D. Hydrogen peroxide
mediates amyloid [beta] protein toxicity. Cell 77: 817–827,
1994.
18. Bowen RL, Smith MA, Harris PLR, Kubat Z, Martins RN,
Castellani RJ, Perry G, and Atwood CS. Elevated luteinizing
hormone expression colocalizes with neurons vulnerable to Alzheimer’s disease pathology. J Neurosci Res 70: 514–518, 2002.

14333c10.pgs

9/29/06

10:32 AM

Page 2057

HORMONES IN ALZHEIMER’S DISEASE
19. Bowen RL, Isley JP, and Atkinson RL. An association of elevated
serum gonadotropin concentrations and Alzheimer disease? J
Neuroendocrinol 12: 351–354, 2000.
20. Bowen RL, Verdile G, Liu TB, Parlow AF, Perry G, Smith MA,
Martins RN, and Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279:
20539–20545, 2004.
21. Bruce–Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola
S, and Mattson MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 141: 3646–3656, 2000.
22. Bukovsky A, Indrapichate K, Fujiwara H, Cekanova M, Ayala
M, Dominguez R, Caudle M, Wimalsena J, Elder R, Copas P,
Foster J, Fernando R, Henley D, and Upadhyaya N. Multiple
luteinizing hormone receptor (LHR) protein variants, interspecies reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in human placenta, pelvic floor and brain, and
possible role for LHR in the development of abnormal pregnancy, pelvic floor disorders and Alzheimer’s disease. Reprod
Biol Endocrin 1: 46, 2003.
23. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G,
and Calabrese V. Nutritional approaches to combat oxidative
stress in Alzheimer’s disease. J Nutr Biochem 13: 444, 2002.
24. Butterfield DA and Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and
consequences involving amyloid [beta]-peptide-associated free
radical oxidative stress. Free Radic Biol Med 32: 1050–1060, 2002.
25. Casadesus G, Webbera KM, Atwood CS, Pappollac MA, Perry
G, Bowen RL, and Smith MA. Luteinizing hormone modulates
cognition and amyloid- deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762: 447–452, 2006.
26. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH,
and Studd JW. Hormonal profiles after the menopause. BMJ 2:
784–787, 1976.
27. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C, and Maggi A. Engineering of a mouse for the
in vivo profiling of estrogen receptor activity. Mol Endocrinol
15: 1104– 1113, 2001.
28. Culmsee C, Vedder H, Ravati A, Junker V, Otto D, Ahlemeyer B,
Krieg J–C, and Krieglstein J. Neuroprotection by estrogens in a
mouse model of focal cerebral ischemia and in cultured neurons:
evidence for a receptor-independent antioxidative mechanism. J
Cereb Blood Flow Metab 19: 1263–1269, 1999.
29. Czlonkowska A, Ciesielska A, Gromadzka G, and Kurkowska–
Jastrzebska I. Estrogen and cytokines production—the possible
cause of gender differences in neurological diseases. Curr
Pharm Des 11: 1017–1030, 2005.
30. Del Cerro S, Garcia–Estrada J, and Garcia–Segura LM. Neuroactive steroids regulate astroglia morphology in hippocampal
cultures from adult rats. Glia 14: 65–71, 1995.
31. Dimayuga FO, Reed JL, Carnero GA, Wang C, Dimayuga ER,
Dimayuga VM, Perger A, Wilson ME, Keller JN, and
Bruce–Keller AJ. Estrogen and brain inflammation: effects on
microglial expression of MHC, costimulatory molecules and cytokines. J Neuroimmunol 161: 123–136, 2005.
32. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE,
Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey
M, Freeman R, and Hays J. Conjugated equine estrogens and
global cognitive function in postmenopausal women: Women’s
Health Initiative Memory Study. JAMA 291: 2959–2968, 2004.
33. Foldvary–Schaefer N, Harden C, Herzog A, and Falcone T. Hormones and seizures. Cleve Clin J Med 71: S11–18, 2004.
34. Foster SC, Daniels C, Bourdette DN, Bebo J, and Bruce F. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J
Neuroimmunol 140: 78–87, 2003.
35. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, and
Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce [beta]-amyloid fibrils. Acta
Neuropathol 84: 225–233, 1992.
36. Garcia–Estrada J, Luquin S, Fernandez AM, and Garcia–Segura
LM. Dehydroepiandrosterone, pregnenolone and sex steroids
downregulate reactive astroglia in the male rat brain after a penetrating brain injury. Int J Dev Neurosci 17: 145–151, 1999.

2057
37. Garcia–Segura LM, Wozniak A, Azcoitia I, Rodriguez JR,
Hutchison RE, and Hutchison JB. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neurosci 89: 567–578, 1999.
38. Gillett MJ, Martins RN, Clarnette RM, Chubb SAP, Bruce DG,
and Yeap BB. Relationship between testosterone, sex hormone
binding globulin and plasma amyloid beta peptide 40 in older
men with subjective memory loss or dementia. J Alzheimer’s Dis
5: 267–269, 2003.
39. Goodenough S, Engert S, and Behl C. Testosterone stimulates
rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein
kinase pathway. Neurosci Lett 296: 49–52, 2000.
40. Goodman Y, Bruce AJ, Cheng B, and Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative
injury, and amyloid beta peptide toxicity in hippocampal neurons. J Neurochem 66: 1836–1844, 1996.
41. Goodman Y and Mattson, MP. Secreted forms of b-amyloid precursor protein protect hippocampal neurons against amyloid bpeptide-induced oxidative injury. Exp Neurol 128: 1–12, 1994.
42. Goodman Y, Steiner MR, Steiner SM, and Mattson MP. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid b-peptide toxicity, and attenuates free radical and calcium
accumulation. Brain Res 654: 171–176, 1994.
43. Gooren LJG. The age-related decline of androgen levels in men:
clinically significant? Br J Urol 78: 763–769, 1996.
44. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R, and
Greengard P. Testosterone reduces neuronal secretion of Alzheimer’s b-amyloid peptides. Proc Natl Acad Sci USA 97: 1202–
1205, 2000.
45. Green PS, Bales K, Paul S, and Bu G. Estrogen therapy fails to
alter amyloid deposition in the PDAPP model of Alzheimer’s
disease. Endocrinology 146: 2774–2781, 2005.
46. Green PS, Yang S–H, Nilsson KR, Kumar AS, Covey DF, and
Simpkins JW. The nonfeminizing enantiomer of 17b-estradiol
exerts protective effects in neuronal cultures and a rat model of
cerebral ischemia. Endocrinology 142: 400–406, 2001.
47. Gridley KE, Green PS, and Simpkins JW. Low concentrations of
estradiol reduce b-amyloid (25–35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 778: 158–165, 1997.
48. Hall ED, Pazara KE, and Linseman KL. Sex differences in
postischemic neuronal necrosis in gerbils. J Cereb Blood Flow
Metab 11: 292–298, 1991.
49. Han T. Inhibitory effect of human chorionic gonadotropin on
lymphocyte blastogenic response to mitogen, antigen and allogeneic cells. Clin Exp Immunol 18: 529–535, 1974.
50. Harman S, Brinton E, Cedars M, Lobo R, Manson J, Merriam G,
Miller V, Naftolin F, and Santoro N. KEEPS: The Kronos Early
Estrogen Prevention Study. Climacteric 8: 3–12, 2005.
51. Harris ME, Hensley K, Butterfield DA, Leedle RA, and Carney
JM. Direct evidence of oxidative injury produced by the Alzheimer’s b-amyloid peptide (1–40) in cultured hippocampal neurons. Exp Neurol 131: 193–202, 1995.
52. Harris–White ME, Chu T, Miller SA, Simmons M, Teter B, Nash
D, Cole GM, and Frautschy SA. Estrogen (E2) and glucocorticoid (Gc) effects on microglia and Ab clearance in vitro and in
vivo. Neurochem Int 39: 435–448, 2001.
53. Hayashi T, Yamada K, Esaki T, Muto E, Chaudhuri G, and Iguchi
A. Physiological concentrations of 17b-estradiol inhibit the synthesis of nitric oxide synthase in macrophages via a receptormediated system. J Cardiovasc Pharmacol 31: 292–298, 1998.
54. Henderson V and Buckwalter J. Cognitive deficits of men and
women with Alzheimer’s disease. Neurology 44: 90–96, 1994.
55. Hogervorst E, Bandelow S, Combrinck M, and Smith AD. Low
free testosterone is an independent risk factor for Alzheimer’s
disease. Exp Gerontol 39: 1633–1639, 2004.
56. Jaffe A, Toran–Allerand C, Greengard P, and Gandy S. Estrogen
regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 269: 13065–13068, 1994.
57. Janowsky JS, Oviatt SK, and Orwoll ES. Testosterone influences
spatial cognition in older men. Behav Neurosci 108: 325–332, 1994.
58. Jellinck P, Hahn E, Norton B, and Fishman J. Catechol estrogen
formation and metabolism in brain tissue: comparison of tritium

14333c10.pgs

9/29/06

10:32 AM

Page 2058

2058

59.
60.

61.

62.
63.

64.
65.

66.

67.
68.

69.
70.
71.
72.

73.
74.
75.

76.

77.

78.
79.

BARRON ET AL.
release from different positions in ring A of the steroid. Endocrinology 115: 1850–1856, 1984.
Katzman R and Saitoh T. Advances in Alzheimer’s disease.
FASEB J 5: 278–286, 1991.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M,
Zonderman A, Bacal C, Donnell Lingle D, and Metter E. A
prospective study of estrogen replacement therapy and the risk
of developing Alzheimer’s disease: The Baltimore Longitudinal
Study of Aging. Neurology 48: 1517–1521, 1997.
Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield
DA, and Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:
1152–1156, 2005.
Kim H–M and Moon Y–H. Human chorionic gonadotropin induces nitric oxide synthase mRNA in mouse peritoneal macrophages. Biochem Biophys Res Commun 229: 548–552, 1996.
Kosaka K, Fujiwara H, Tatsumi K, Yoshioka S, Sato Y, Egawa H,
Higuchi T, Nakayama T, Ueda M, Maeda M, and Fujii S. Human
chorionic gonadotropin (HCG) activates monocytes to produce
interleukin-8 via a different pathway from luteinizing hormone/
HCG receptor system. J Clin Endocrinol Metab 87: 5199–5208,
2002.
Kumru S, Godekmerdan A, and Yilmaz B. Immune effects of
surgical menopause and estrogen replacement therapy in perimenopausal women. J Reprod Immunol 63: 31–38, 2004.
Kuo YM, Webster S, Emmerling M, De Lima N, and Roher AE.
Irreversible dimerization/tetramerization and post-translational
modifications inhibit proteolytic degradation of A beta peptides of
Alzheimer’s disease. Biochim Biophys Acta 1406: 291–298, 1998.
Lammers C–H, Schweitzer P, Facchinetti P, Arrang J–M,
Madamba SG, Siggins GR, and Piomelli D. Arachidonate 5lipoxygenase and its activating protein: Prominent hippocampal
expression and role in somatostatin signaling. J Neurochem 66:
147–152, 1996.
Lendon CL, Ashall F, and Goate AM. Exploring the etiology of
Alzheimer disease using molecular genetics. JAMA 277: 825–
831, 1997.
Levin–Allerhand JA, Lominska CE, Wang J, and Smith JD.
17Alpha-estradiol and 17beta-estradiol treatments are effective
in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice. J Alzheimer’s Dis 4: 449–457, 2002.
Li R, Shen Y, Yang LB, Lue LF, Finch C, and Rogers J. Estrogen
enhances uptake of amyloid beta-protein by microglia derived
from the human cortex. J Neurochem 75: 1447–1454, 2000.
Liehr JG and Roy D. Free radical generation by redox cycling of
estrogens. Free Radic Biol Med 8: 415–423, 1990.
Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr
Rev 21: 40–54, 2000.
Lin J, Lojun S, Lei ZM, Wu WX, Peiner SC, and Rao CV. Lymphocytes from pregnant women express human chorionic gonadotropin/luteinizing hormone receptor gene. Mol Cell Endocrinol 111: R13–R17, 1995.
Maki PM. A systematic review of clinical trials of hormone therapy on cognitive function. Effects of age at initiation and progestin use. Ann NY Acad Sci 1052: 182–197, 2005.
Manev H, Uz T, Sugaya K, and Qu T. Putative role of neuronal 5lipoxygenase in an aging brain. FASEB J 14: 1464–1469, 2000.
Manly JJ, Merchant CA, Jacobs DM, Small S, Bell K, Ferin M,
and Mayeux R. Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology 54: 833–837,
2000.
Martins RN, Harper CG, Stokes GB, and Masters, CL. Increased
cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J Neurochem 46:
1042–1045, 1986.
Massafra C, Gioia D, De Felice C, Muscettola M, Longini M,
and Buonocore G. Gender-related differences in erythrocyte glutathione peroxidase activity in healthy subjects. Clin Endocrinol
57: 663–667, 2002.
Mastrogiacomo I, Geghali G, Foresta C, and Ruzza G. Andropause: incidence and pathogenesis. Arch Androl 9: 293–296,
1982.
Mattson MP. Central role of oxy-radicals in the mechanism of amyloid beta-peptide cytotoxicity. Alzheimer Dis Rev 2: 1–14, 1997.

80. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, and
Rydel RE. Evidence for excitoprotective and intraneuronal
calcium-regulating roles for secreted forms of the beta-amyloid
precursor protein. Neuron 10: 243–254, 1993.
81. McGeer PL and McGeer, EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other
neurodegenerative diseases. Brain Res Rev 21: 195–218, 1995.
82. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ,
Beyreuther K, Bush AI, and Masters CL. Soluble pool of Abeta
amyloid as a determinant of severity of neurodegeneration in
Alzheimer’s disease. Ann Neurol 46: 860–866, 1999.
83. Mele PG, Dada LA, Paz C, Neuman I, Cymeryng CB, Mendez
CF, Finkielstein CV, Cornejo Maciel F, and Podesta EJ. Involvement of arachidonic acid and the lipoxygenase pathway in mediating luteinizing hormone-induced testosterone synthesis in rat
Leydig cells. Endocr Res 23: 15–26, 1997.
84. Mellon SH, Griffin LD, and Compagnone NA. Biosynthesis and
action of neurosteroids. Brain Res Rev 37: 3–12, 2001.
85. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC,
Simpson ER, and Davis SR. Adipose aromatase gene expression
is greater in older women and is unaffected by postmenopausal
estrogen therapy. Menopause 12: 210–215, 2005.
86. Monteiro SC, Matte C, Delwing D, and Wyse ATS. Ovariectomy
increases Na+, K+-ATPase, acetylcholinesterase and catalase in
rat hippocampus. Mol Cell Endocrinol 236: 9–16, 2005.
87. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M,
Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M,
Thomas R, and Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 283: 1007–1015, 2000.
88. Neaves WB, Johnson L, Porter JC, Parker CRJ, and Petty CS.
Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 59:
756– 763, 1984.
89. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK,
Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, and Smith MA. Oxidative damage is the
earliest event in Alzheimer disease. J Neuropathol Exp Neurol
60: 759–767, 2001.
90. Özgönül M, Öge A, Sezer E, Bayraktar F, and Sözmen E. The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovarectomized female rats. Endocrine Res 29: 183–189, 2003.
91. Paganini–Hill A and Henderson VW. Estrogen deficiency and
risk of Alzheimer’s disease in women. Am J Epidemiol 140:
256–261, 1994.
92. Pangalos MN, Jacobsen SJ, and Reinhart PH. Disease modifying
strategies for the treatment of Alzheimer’s disease targeted at
modulating levels of the beta-amyloid peptide. Biochem Soc
Trans 33: 553–558, 2005.
93. Paul SM and Axelrod J. Catechol estrogens: presence in brain
and endocrine tissues. Science 197: 657–659, 1977.
94. Payne AH and Hales DB. Overview of steroidogenic enzymes in
the pathway from cholesterol to active steroid hormones. Endocr
Rev 25: 947–970, 2004.
95. Petanceska SS, Nagy V, Frail D, and Gandy S. Ovariectomy and
17b-estradiol modulate the levels of Alzheimer’s amyloid b peptides in brain. Exp Gerontol 35: 1317–1325, 2000.
96. Pike CJ, Cummings BJ, and Cotman, CW. Early association of
reactive astrocytes with senile plaques in Alzheimer’s disease.
Exp Neurol 132: 172–179, 1995.
97. Pratico D and Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med
109: 577–585, 2000.
98. Pratico D, Clark CM, Liun F, Lee VYM, and Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a
possible predictor of Alzheimer disease. Arch Neurol 59: 972–
976, 2002.
99. Qu T, Uz T, and Manev H. Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging 21:
647–652, 2000.
100. Ruitenberg A, Ott A, van Swieten JC, Hofman A, and Breteler
MMB. Incidence of dementia: does gender make a difference?
Neurobiol Aging 22: 575–580, 2001.

14333c10.pgs

9/29/06

10:32 AM

Page 2059

HORMONES IN ALZHEIMER’S DISEASE
101. Ruiz–Larrea BM, Ma Leal A, Liza M, Lacort M, and de Groot
H. Antioxidant effects of estradiol and 2-hydroxyestradiol on
iron-induced lipid peroxidation of rat liver microsomes. Steroids
59: 383–388, 1994.
102. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, and Shun
Shimohama. Estradiol protects mesencephalic dopaminergic
neurons from oxidative stress-induced neuronal death. J Neurosci Res 54: 707–719, 1998.
103. Schmidt AJ, Krieg J–C, and Vedder, H. Effects of steroid hormones on catalase activity in neuronal and glial cell systems.
Eur Neuropsychopharmacol 15: 177–183, 2005.
104. Schmidt AJ, Krieg J–C, and Vedder H. Differential effects of glucocorticoids and gonadal steroids on glutathione levels in neuronal and glial cell systems. J Neurosci Res 67: 544–550, 2002.
105. Schuessel K, Leutner S, Cairns NJ, Muller WE, and Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer’s disease brain. J Neur Trans 111: 1167–1182,
2004.
106. Shi J, Panickar KS, Yang S–H, Rabbani O, Day AL, and Simpkins JW. Estrogen attenuates over-expression of -amyloid precursor protein messenger RNA in an animal model of focal ischemia. Brain Res 810: 87–92, 1998.
107. Shirai F, Kawaguchi M, Yutsudo M, and Dohi Y. Human peripheral blood polymorphonuclear leukocytes at the ovulatory period
are in an activated state. Mol Cell Endocrinol 196: 21–28, 2002.
108. Short RA, Bowen RL, O’Brien PC, and Graff–Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease.
Mayo Clin Proc 76: 906–909, 2001.
109. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene
JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM,
Wassertheil–Smoller S, and Wactawski–Wende J. Estrogen plus
progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA
289: 2651–2662, 2003.
110. Signorelli SS, Neri S, Sciacchitano S, Pino LD, Costa MP,
Marchese G, Celotta G, Cassibba N, Pennisi G, and Caschetto S.
Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 53: 77–82, 2006.
111. Sih R, Morley, JE, Kaiser FE, Perry HM, III, Patrick P, and Ross
C. Testosterone replacement in older hypogonadal men: a 12month randomized controlled trial. J Clin Endocrinol Metab 82:
1661–1667, 1997.
112. Singh M. Mechanisms of progesterone-induced neuroprotection.
Ann NY Acad Sci 1052: 145–151, 2005.
113. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlak
SL, Tabaton M, and Perry G. Amyloid- deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212–2215, 1998.
114. Smith–Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR,
Rydel RE, and Mattson MP. Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem 63: 781–784, 1994.
115. Subbiah M, Kessel B, Agrawal M, Rajan R, Abplanalp W, and Rymaszewski Z. Antioxidant potential of specific estrogens on lipid
peroxidation. J Clin Endocrinol Metab 77: 1095–1097, 1993.
116. Sugioka K, Shimosegawa Y, and Nakano, M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS
Lett 210: 37–39, 1987.
117. Tan RS and Pu SJ. A pilot study on the effects of testosterone in
hypogonadal aging male patients with Alzheimer’s disease.
Aging Male 6: 13, 2003.
118. Tang MX, Jacobs D, Stern Y, Marder K, Schofield PR, Gurland
B, Andrews H, and Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet
348: 429, 1996.
119. Taniguchi H, Uenoyama Y, Miyamoto Y, and Okuda K. The
lipoxygenase pathways are involved in LH-stimulated progesterone production in bovine corpus luteum. Prostaglandins Other
Lipid Mediat 67: 49–60, 2002.
120. Thomas T, Bryant M, Clark L, Garces A, and Rhodin J. Estrogen
and raloxifene activities on amyloid-induced inflammatory reaction. Microvas Res 61: 28–39, 2001.
121. Thomas T, Thomas G, McLendon C, Sutton T, and Mullan M.

2059

122.
123.
124.
125.

126.

127.

128.
129.
130.

131.

132.
133.

134.
135.
136.
137.

Beta-amyloid-mediated vasoactivity and vascular endothelial
damage. Nature 380: 168–171, 1996.
Tseroias K and Merino G. Andropause and the aging male. Arch
Androl 40: 87–93, 1998.
Uz T, Pesold C, Longone P, and Manev, H. Aging-associated upregulation of neuronal 5-lipoxygenase expression: putative role
in neuronal vulnerability. FASEB J 12: 439–449, 1998.
Vedder H, Anthes N, Stumm G, Wurz C, Behl C, and Krieg J–C.
Estrogen hormones reduce lipid peroxidation in cells and tissues
of the central nervous system. J Neurochem 72: 2531–2538, 1999.
Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F,
Brusadelli A, Viviani B, Ciana P, and Maggi A. Estrogen prevents the lipopolysaccharide-induced inflammatory response in
microglia. J Neurosci 21: 1809–1818, 2001.
Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, and Martins RN. The role of beta amyloid in Alzheimer’s disease: still a
cause of everything or the only one who got caught? Pharmacol
Res 50: 397–409, 2004.
Verdile G, Gandy SE, Fraser P, Atwood CS, and Martins RN. The
presenilins and their role in amyloid- generation production.
In: Focus on Alzheimer’s Disease Research, edited by Welsh
E.M. New York, Nova Science Publishers, 2003, pp. 167–210.
Veurink G, Fuller SJ, Atwood CS and Martins RN. Genetics,
lifestyle and the roles of amyloid b and oxidative stress in Alzheimer’s disease. Ann Hum Biol 30: 639–667, 2003.
Vural P, Akgul C, and Canbaz M. Effects of menopause and tibolone on antioxidants in postmenopausal women. Ann Clin
Biochem 42: 220–223, 2005.
Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, Yu HY,
Wang SJ, and Liu HC. Effects of estrogen on cognition, mood,
and cerebral blood flow in AD: a controlled study. Neurology 54:
2061–2066, 2000.
Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F,
Checler F, Buxbaum J, Chait BT, Thinakaran G, Sisodia SS,
Wang R, Greengard P, and Gandy S. Estrogen reduces neuronal
generation of Alzheimer beta-amyloid peptides. Nat Med 4:
447–451, 1998.
Yagi K. Female hormones act as natural antioxidants: a survey of
our research. Acta Biochim Polon 44: 701–710, 1997.
Yue X, Lu M, Lancaster T, Cao P, Honda S–I, Staufenbiel M,
Harada N, Zhong Z, Shen Y, and Li R. Brain estrogen deficiency
accelerates Ab plaque formation in an Alzheimer’s disease animal model. Proc Natl Acad Sci USA 102: 19198–19203, 2005.
Zhang W, Lei ZM, and Rao CV. Immortalized hippocampal cells
contain functional luteinizing hormone/human chorionic gonadotropin receptors. Life Sci 65: 2083–2098, 1999.
Zhang Y, Lei Z, and Rao C. Functional importance of human
monocyte luteinizing hormone and chorionic gonadotropin receptors. (Abstract) J Soc Gynecol Invest 6, 1999.
Zhang YM, Rao CV, and Lei ZM. Macrophages in human reproductive tissues contain luteinizing hormone/human chorionic gonadotropin receptors. Am J Reprod Immunol 49: 93–100, 2003.
Zheng H, Xu H, Uljon SN, Gross R, Hardy K, Gaynor J, Lafrancois J, Simpkins J, Refolo LM, Petanceska S, Wang R, and Duff
K. Modulation of A peptides by estrogen in mouse models. J
Neurochem 80: 191–196, 2002.

Address reprint requests to:
Professor Ralph Martins
Centre of Excellence for
Alzheimer’s Disease Research and Care
Sir James McCusker Alzheimer’s Disease Research Unit
Edith Cowan University
100 Joondalup Drive
6027, Joondalup, Australia
E-mail: r.martins@ecu.edu.au
Date of first submission to ARS Central, May 27, 2006; date of
acceptance, June 1, 2006.

14333c10.pgs

9/29/06

10:32 AM

Page 2060

This article has been cited by:
1. Dan R. Laks. 2009. Assessment of chronic mercury exposure within the U.S. population, National Health and Nutrition
Examination Survey, 1999–2006. BioMetals . [CrossRef]
2. E.-S. Y. Lee, Z. Yin, D. Milatovic, H. Jiang, M. Aschner. 2009. Estrogen and Tamoxifen Protect against Mn-Induced Toxicity
in Rat Cortical Primary Cultures of Neurons and Astrocytes. Toxicological Sciences 110:1, 156-167. [CrossRef]
3. Professor D. Allan Butterfield . 2006. Oxidative Stress in Neurodegenerative DisordersOxidative Stress in Neurodegenerative
Disorders. Antioxidants & Redox Signaling 8:11-12, 1971-1973. [Citation] [PDF] [PDF Plus]

